Keyword: Vasant Narasimhan
Novartis CEO Vas Narasimhan says narrowing its focus to just a few therapeutic areas wouldn't be healthy for the business in the long run.
Novartis last year said its forthcoming SMA gene therapy could be cost-effective at up to $5 million. Now, its CEO says the price will be "far lower."
New models are needed to assess the value of gene and cell therapies and provide reimbursement, Novartis CEO Vas Narasimhan says.
Cosentyx and Entresto delivered strong growth again, but Novartis CEO Vas Narasimhan took pains to explain a death case in a Zolgensma trial.
Greek investigators were probing charges that Novartis bribed politicians for preferential pricing of its drugs. But now their case is falling apart.
Novartis CEO Vas Narasimhan plans to spend $10 billion a year on acquisitions as he pursues high-growth markets such as gene therapy.
Novartis’ Cosentyx has beaten out rivals from Eli Lilly and J&J to land a psoriasis nod in China.
To focus as what CEO Vas Narasimhan calls “a medicines company,” Novartis made a series of M&A decisions in 2018.
Sandoz head Richard Francis said he can't commit to what CEO Vas Narasimhan calls "a multiyear transformation program" for the generics unit.
Pharmas often face scrutiny on price hikes for old drugs, but now investors are asking Novartis about high prices for groundbreaking new drugs.